These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Highly active antiretroviral therapy leads to a significant but delayed increase of CD45RA+ T-helper cells. Degen O; Stellbrink HJ; Lauer J; van Lunzen J AIDS; 1998 Sep; 12(13):1715-6. PubMed ID: 9764793 [No Abstract] [Full Text] [Related]
3. How does HIV overcome the body's T cell bodyguards? Balter M Science; 1997 Nov; 278(5342):1399-400. PubMed ID: 9411761 [No Abstract] [Full Text] [Related]
4. Can the body control HIV infection without drugs? Check E Newsweek; 2000 Oct; 136(15):59. PubMed ID: 11184537 [No Abstract] [Full Text] [Related]
5. Anti-HIV agents. Is FOTO a treatment interruption that works? TreatmentUpdate; 2005; 17(5):10-1. PubMed ID: 17219661 [No Abstract] [Full Text] [Related]
6. Efficacy of highly active antiretroviral therapy in nonclinical trial setting of a developing Caribbean country. Kumar A; Kilaru KR; Sippy N; Carter AO; Roach TC J Acquir Immune Defic Syndr; 2005 Sep; 40(1):114-6. PubMed ID: 16123695 [No Abstract] [Full Text] [Related]
7. Down or out in blood and lymph? Wain-Hobson S Nature; 1997 May; 387(6629):123-4. PubMed ID: 9144275 [No Abstract] [Full Text] [Related]
8. HIV therapeutics: points from the recent literature. Laurence J AIDS Read; 2003 Jul; 13(7):305, 307. PubMed ID: 12889448 [No Abstract] [Full Text] [Related]
9. Can immune systems be trained to fight HIV? Balter M Science; 1999 Nov; 286(5444):1470-11. PubMed ID: 10610544 [No Abstract] [Full Text] [Related]
10. [Antiretroviral therapy in patients infected with HIV-1]. Corti ME Medicina (B Aires); 1998; 58 Suppl 1():49-56. PubMed ID: 9674248 [No Abstract] [Full Text] [Related]
11. Monitoring HIV-1 treatment in immune-cell subsets with ultrasensitive fluorescence-in-situ hybridisation. Patterson BK; Czerniewski MA; Pottage J; Agnoli M; Kessler H; Landay A Lancet; 1999 Jan; 353(9148):211-2. PubMed ID: 9923887 [No Abstract] [Full Text] [Related]
12. Total lymphocyte count as a possible surrogate of CD4 cell count to prioritize eligibility for antiretroviral therapy among HIV-infected individuals in resource-limited settings. Bedell R; Heath KV; Hogg RS; Wood E; Press N; Yip B; O'Shaughnessy MV; Montaner JS Antivir Ther; 2003 Oct; 8(5):379-84. PubMed ID: 14640384 [TBL] [Abstract][Full Text] [Related]
13. The case for conservative management of early HIV disease. Burman WJ; Reves RR; Cohn DL JAMA; 1998 Jul; 280(1):93-5. PubMed ID: 9660372 [No Abstract] [Full Text] [Related]
14. High rebound of plasma and cellular HIV load after discontinuation of triple combination therapy. Jubault V; Burgard M; Le Corfec E; Costagliola D; Rouzioux C; Viard JP AIDS; 1998 Dec; 12(17):2358-9. PubMed ID: 9863885 [No Abstract] [Full Text] [Related]
15. Antiretroviral rounds. CD4 count 423, viral load 12,000: time to treat anyway? Hodder S; Frank I AIDS Clin Care; 2006 Jun; 18(6):59-60. PubMed ID: 16791955 [No Abstract] [Full Text] [Related]
16. Immune control of HIV-1 after early treatment of acute infection. Rosenberg ES; Altfeld M; Poon SH; Phillips MN; Wilkes BM; Eldridge RL; Robbins GK; D'Aquila RT; Goulder PJ; Walker BD Nature; 2000 Sep; 407(6803):523-6. PubMed ID: 11029005 [TBL] [Abstract][Full Text] [Related]
17. Discordant movement of CD4-positive T-cell count in HIV-1 infected patients with HAART failure. Okano A; Matsuda M; Chiba T; Moriya K; Yamada K; Sugiura W Jpn J Infect Dis; 2002 Apr; 55(2):62-5. PubMed ID: 12082315 [No Abstract] [Full Text] [Related]
18. Principles of treating HIV. Johnson D S Afr Med J; 2000 Mar; 90(3):227-30. PubMed ID: 10853393 [No Abstract] [Full Text] [Related]
19. IL-2 therapy: potential impact of the CD4 cell count at initiation on clinical efficacy--results from the ANRS CO4 cohort. Fontas E; Kousignian I; Pradier C; Poizot-Martin I; Durier C; Weiss L; Levy Y; Costagliola D; ; J Antimicrob Chemother; 2010 Oct; 65(10):2215-23. PubMed ID: 20702463 [TBL] [Abstract][Full Text] [Related]
20. Immune reconstitution in the HAART era, Part 1: Immune abnormalities in HIV/AIDS. Agnoli MM J Assoc Nurses AIDS Care; 2000; 11(1):78-81. PubMed ID: 10670009 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]